Efficacy and Safety of a Desensitization Treatment With Rituximab and Immunoglobulin in Hyperimmunized Patients Awaiting a Cadaveric Kidney Transplantation
Transplantation Proceedings · 2025
DOI: 10.1016/j.transproceed.2024.12.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplantation Proceedings, 2025. Verfasst von Elena González García und 6 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Nefrología, Hospital Universitario La Paz, Madrid, Spain. Electronic address: mariaelena.gonzalez.garcia@salud.madrid.org. Hauptthemen laut MEDLINE: Rituximab, Kidney Transplantation, Desensitization, Immunologic, Immunoglobulins, Intravenous. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Patients on a kidney transplant waiting list with antibodies against more than 80% of a panel reactive antibody (PRA) are difficult to transplant, even with national or regional programs. Desensitization treatment with high-dose intravenous immunoglobulin and rituximab could be offered to patients with a long waiting time for a cadaveric donor to improve their odds of finding a kidney. METHODS: This was a retrospective, single-center study including all hyperimmunized patients on the waiting list for a cadaveric kidney donor who received a desensitization treatment between 2010 and 2020. Eight patients (50% male patients, mean age = 41.5±16.4 years) were desensitized with intravenous immunoglobulin and rituximab. Seventy-five percent of the patients had received a previous transplant. The median PRA calculated was 98%. The mean follow-up time after transplantation was 67 months. RESULTS: No patient presented significant side effects to desensitization treatment. Seven of the 8 patients (87.5%) received a transplant from a cadaveric donor, in a median 8 months after desensitization. In the immediate post-transplant period, there were two graft losses (28.6%) due to non-immunological causes (1 venous thrombosis in a patient with a coagulation disorder and 1 primary graft failure). Creatinine levels at 1 and 5 years were 1.4 ± 0.2 mg/dL and 1.7 ± 0.6 mg/dL, respectively. There were no episodes of acute rejection. No patient developed cancer during the follow-up. CONCLUSIONS: Desensitization treatment with immunoglobulin and rituximab on hyperimmunized patients on the cadaveric transplant waiting list is a safe and effective treatment that increases the chances of achieving a kidney transplant in highly sensitized patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Servicio de Nefrología, Hospital Universitario La Paz, Madrid, Spain. Electronic address: mariaelena.gonzalez.garcia@salud.madrid.org.
- Servicio de Nefrología, Hospital Universitario La Paz, Madrid, Spain.
- Servicio de Inmunología, Hospital 12 Octubre, Madrid, Spain.
Zitieren
APA
González García, E., López Oliva, M., Mancebo, E., Santana, M. J., León Machado, L. M., Fuentes Fernández, C., & Jiménez, C. (2025). Efficacy and Safety of a Desensitization Treatment With Rituximab and Immunoglobulin in Hyperimmunized Patients Awaiting a Cadaveric Kidney Transplantation. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2024.12.001
Vancouver
González García E, López Oliva M, Mancebo E, Santana MJ, León Machado LM, Fuentes Fernández C, et al. Efficacy and Safety of a Desensitization Treatment With Rituximab and Immunoglobulin in Hyperimmunized Patients Awaiting a Cadaveric Kidney Transplantation. Transplantation Proceedings. 2025. doi:10.1016/j.transproceed.2024.12.001
BibTeX
@article{GonzlezGarca2025,
author = {González García, Elena and López Oliva, María and Mancebo, Esther and Santana, María José and León Machado, Lina María and Fuentes Fernández, Cristina and Jiménez, Carlos},
title = {Efficacy and Safety of a Desensitization Treatment With Rituximab and Immunoglobulin in Hyperimmunized Patients Awaiting a Cadaveric Kidney Transplantation},
journal = {Transplantation Proceedings},
year = {2025},
doi = {10.1016/j.transproceed.2024.12.001}
}
EUVIMED